Merck won't partner with Gilead in mTNBC when they
Post# of 154045
(Total Views: 430)
Posted On: 06/02/2025 7:49:19 PM
Merck won't partner with Gilead in mTNBC when they have their own TROP2 ADC, Sacituzumab tirumotecan. They are developing it as a monotherapy as well as in combination with pembro.
Late last year, Merck also jumped onto the PD-1/VEGF bispecific bandwagon with a licensing deal with a Chinese company.
Late last year, Merck also jumped onto the PD-1/VEGF bispecific bandwagon with a licensing deal with a Chinese company.
(2)
(0)